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CCN family member 1 (CCN1), also known as cysteine-rich angiogenic inducer 61 (CYR61), belongs to the extracellular
matrix-associated CCN protein family. The diverse functions of these proteins include regulation of cell migration,
adhesion, proliferation, differentiation and survival/apoptosis, induction of angiogenesis and cellular senescence. Their
functions are partly overlapping, largely non-redundant, cell-type specific, and depend on the local microenvironment. To
elucidate the role of CCN1 in the crosstalk between stromal cells and myeloma cells, we performed co-culture
experiments with primary mesenchymal stem cells (MSC) and the interleukin-6 (IL-6)-dependent myeloma cell line INA-6.
Here we show that INA-6 cells display increased transcription and induction of splicing of intron-retaining CCN1 pre-mRNA
when cultured in contact with MSC. Protein analyses confirmed that INA-6 cells co-cultured with MSC show increased
levels of CCN1 protein consistent with the existence of a pre-mature stop codon in intron 1 that abolishes translation of
unspliced mRNA. Addition of recombinant CCN1-Fc protein to INA-6 cells was also found to induce splicing of CCN1
pre-mRNA in a concentration-dependent manner. Only full length CCN1-Fc was able to induce mRNA splicing of all
introns, whereas truncated recombinant isoforms lacking domain 4 failed to induce intron splicing. Blocking
RGD-dependent integrins on INA-6 cells resulted in an inhibition of these splicing events. These findings expand
knowledge on splicing of the proangiogenic, matricellular factor CCN1 in the tumor microenvironment. We propose
that contact with MSC-derived CCN1 leads to splicing and enhanced transcription of CCN1 which further contributes to
the translation of angiogenic factor CCN1 in myeloma cells, supporting tumor viability and myeloma bone disease.
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CCN family member 1 (CCN1) belongs to the modular
extracellular matrix (ECM)-associated CCN protein family
named according to three prototypic members (cysteine-
rich angiogenic inducer 61 CYR61/CCN1, connective tissue
growth factor CTGF/CCN2, and nephroblastoma overex-
pressed NOV/CCN3). Proteins share 30-50% primary se-
quence homology and are organized into four discrete
domains with sequence relationships to insulin-like growth
factor binding proteins (IGFBPs), the von Willebrand factor
type C (vWC) repeat domain, the thrombospondin type I
repeat (TSR) domain, and a carboxy-terminal (CT) domain
containing a cysteine-knot motif [1]. These immediate early
gene-encoded proteins are regulated by growth factors and
hormones (e.g. transforming growth factor-beta (TGFβ),* Correspondence: n-schuetze.klh@uni-wuerzburg.de
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article, unless otherwise stated.tumor-necrosis factor alpha (TNFα)), 1,25-dihydroxyvita-
min D3, and mechanical forces [2-4]. Their functions are
partly overlapping, yet appear to be mostly non-redundant,
and are expressed in a cell-type specific manner dependent
on the local microenvironment. CCN1 shows complex
functionality due to specific interactions with a variety of
binding partners including integrins and proteoglycans [5].
CCN1 knockout is embryonically lethal in many pups due
to alteration of chorioallantoic fusion, whereas most perish
due to hemorrhage between E11.5 and E14.5 with only a
very few being born alive, but dying within 24 h [6]. The
multiple functions of CCN1 include regulation of cell mi-
gration, adhesion, proliferation, differentiation and survival/
apoptosis, cellular senescence and ECM protein synthesis
[4,7-10]. Through these diversity of functions, CCN1 mod-
ulates important biological processes including develop-
mental processes, angiogenesis and tissue regeneration, and
plays a role in pathological conditions such as wound heal-
ing, vascular diseases, inflammation, fibrosis and tumorntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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an oncogene, e.g. in mammary cancer, and as a tumor sup-
pressor [10,12,13]. The importance of CCN1 in tumorigen-
esis originates from its diverse molecular functions which
influence tumor development and metastasis by modulat-
ing angiogenesis, epithelial mesenchymal transition (EMT),
and anoikis resistance [14]. Expression of CCN1 in tumors
is characterized by deregulated protein levels, either of full
length or truncated isoforms, whose diversity is expanded
by post-translational processing, as well as by alternative
splicing [15,16]. In the case of breast cancer tissue, alterna-
tive splicing of intron 3 has been linked to tumor progres-
sion and was regulated in tumor cells by exposure to
hypoxic and acidic microenvironments [16-18]. In order to
explain the apparent mismatch between the number of
genes (25,000) versus the number of proteins that exist in
humans (90,000), the last decade has seen extensive re-
search about mechanisms that underlie the complexity of
the proteome such as posttranslational modification mech-
anisms and alternative splicing. Splicing regulatory factors
are currently under intensive research as “oncogenic alter-
native splicing switches” which may serve as promising
new treatment targets in oncology [16]. In this context al-
ternative splicing as a means of producing a biological di-
versity of CCN proteins has been discussed [15].
Multiple Myeloma (MM) is a B-cell malignancy charac-
terized by clonal proliferation of a terminally-differentiated
plasma cell, and is associated with immunoglobulin light
chain or heavy chain production. MM is the second most
common hematological malignancy and is accompanied by
a high mortality and morbidity, despite recent progress in
treatment modalities [19,20]. A major devastating compli-
cation of this disease is myeloma bone disease, which is
associated with increased mortality and is driven by inter-
action between myeloma cells and cells of the bone marrow
microenvironment, leading to imbalanced bone remodeling
[21]. Bone metabolism is orchestrated by a complex inter-
action between bone-forming mesenchymal stem cells
(MSC) and their osteogenic offspring (osteoblasts/osteo-
cytes), and monocyte-derived osteoclasts. Bone formation is
driven by at least three major osteogenic pathways, namely
parathyroid hormone 1 receptor (PTH1R), bone morpho-
genetic proteins (BMP) and their receptors, and the wnt/
frz/LRP5/6 pathway, along with sclerostin (SOST) and
dickkopf-1 (DKK-1) which act as potent inhibitors of the
wnt pathway [22]. Osteoclast development is dependent on
colony-stimulating factors and receptor activator of NFĸB
ligand (RANKL) produced by osteoblasts [23]. Myeloma
cells also produce RANKL or RANKL-inducing molecules
thereby initiating the classical vicious cycle of tumor-
initiated osteolysis [24]. Myeloma bone disease dissociates
bone resorption from bone formation and disintegrates the
cooperation between osteogenic differentiation and angio-
genesis. This supports myeloma progression and results inthe inhibition of bone regeneration [25]. Bone regeneration
is inhibited by myeloma-associated secreted inhibitors
like DKK-1, secreted frizzled related proteins 2 and 3
(SFRP2/3), SOST and activin which interfere with
osteogenic differentiation pathways [26,27]. Conversely,
osteoblasts, for largely unknown reasons, can inhibit
myeloma cell growth, as has been shown for MM treat-
ment with the proteasome inhibitor bortezomib, which
supports osteoblast function via enhanced vitamin D re-
ceptor signaling [28,29]. Antibody and antagonist-based
neutralization strategies of osteogenic inhibitors (DKK-
1, activin, SOST) are currently under development for
the management of myeloma bone disease [30-33].
Myeloma cells are dependent on and influenced by
stromal support. MSC have been described both as effi-
cient supporters for myeloma cell growth and survival,
and as potent disease modifiers that can inhibit MM cell
growth [34]. MSC from MM patients exhibited intrinsic
defects in osteogenic differentiation, which may permis-
sively support MM expansion [35]. Moreover, overpro-
duction of e.g. GDF15 by MSC, as seen in MM patients,
is a powerful protective mechanism for MM cells and is
linked to patient survival [36]. In contrast, intra-bone in-
jection of MSC inhibited MM progression in preclinical
settings [37]. Hence, there is a huge clinical need to un-
ravel the multiple effects induced by tumor-MSC inter-
actions and to demonstrate their impact on the course
of disease.
In the present study, we investigated the expression of
CCN1 in myeloma cells under conditions of a tumor-
supportive microenvironment. We describe for the first
time that myeloma cells display intron retention in
CCN1 mRNA, followed by splicing of all introns, en-
hanced transcription and consecutive translation upon
contact with MSC. We also demonstrate that this effect
can be exerted by recombinant CCN1 protein which fur-
ther enhances myeloma cell viability.
Results
Contact with MSC induces CCN1 pre-mRNA splicing,
transcription, and CCN1 protein production in INA-6
multiple myeloma cells
To elucidate the role of CCN1 in the crosstalk between
stromal cells and myeloma tumor cells, we performed
co-culture experiments with primary MSC and the
interleukin-6 (IL-6)-dependent myeloma cell line INA-6
[38]. Using intron-4 spanning primers (CCN1 4-5), INA-
6 cells co-cultured with MSC expressed two alternate
mRNA forms of different sizes (321 bp, 206 bp) com-
pared to INA-6 control cells, which showed only a single
variant (321 bp) (Figure 1A). Sequence analyses con-
firmed that the two variants represented the spliced (206
bp) and unspliced (321 bp) forms of CCN1 mRNA. To
evaluate if splicing is restricted to intron 4, additional
Figure 1 Splicing of CCN1 pre-mRNA and protein expression is induced by MSC contact in INA-6 cells. INA-6 cells were either cultured
alone (-) or in the presence of MSC (+). After 24 h of co-culture, INA-6 cells were separated from MSC by washing. (A) Splicing pattern of CCN1
pre-mRNA was investigated by semi-quantitative PCR with four different intron-spanning primers in five independent experiments. The primers
are labeled according to their exon positions. INA-6 control cells (-) express the intron-retaining pre-mRNA whereas co-cultured INA-6 cells (+)
show an increased expression of the intron-free transcript. Housekeeping gene EEF1A1 served as control. Different gels are indicated by dashed
lines. (B) CCN1 protein expression in INA-6 cells. Western blot analysis of three independent experiments shows an increased protein expression
of CCN1 in INA-6 cells after MSC contact. Re-blotting for β-actin was used to confirm equal loading of protein.
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exon-intron transitions (Table 1). In each case, INA-6
control cells expressed the intron-retaining pre-mRNA,
whereas INA-6 cells in contact with MSC expressed
both the intron-retaining pre-mRNA and, to a greater
extent, the intron-free isoform (Figure 1A). Overall, this
pattern indicates that each intron of CCN1 is affected by
splicing upon contact with MSC. This was additionally
confirmed by long-range PCR, as the combination of theTable 1 Primer sequences and conditions of semi-quantitativ
Gene product Primer 5′-3′ sequence Annealing
CCN1 1-2 Reverse TCACCCTTCTCCACTTGACC
Forward AGTCCTCGTTGAGCTGCTTG
CCN1 2-3 Reverse ACCGCTCTGAAGGGGATCT
Forward GGGACACAGAGGAATGCAG
CCN1 3-4 Reverse GGCAGACCCTGTGAATATAA
Forward CAGGGTTGTCATTGGTAACT
CCN1 4-5 Reverse CAACCCTTTACAAGGCCAGA
Forward TGGTCTTGCTGCATTTCTTG
EEF1A1 Reverse CTGTATTGGATTGCCACG
Forward AGACCGTTCTTCCACCACTG5′-primer CCN 1-2 and the 3′-primer CCN 4-5 showed
two bands representing intron-retained and intron-free
CCN1 mRNA (data not shown). To elucidate if tran-
scription of CCN1 is enhanced in INA-6 cells after MSC
contact, qPCR analyses were performed. CCN1 mRNA
expression in INA-6 cells co-cultured with MSC in-
creased significantly by 5.3 fold (SD: 1.7-14.2: p < 0.001
calculated with REST [39]), with a high donor variability
(2.4 to 17.3 fold), compared to control cells (data note PCR
temperature (°C) Length of PCR product (bp) mRNA isoform
56 470 Intron-retained
153 Intron-free
56 502 Intron-retained
153 Intron-free
50 612 Intron-retained
481 Intron-free
54 321 Intron-retained
206 Intron-free
54 369
Figure 2 Exogenous stimulation by recombinant CCN1-Fc
induces splicing of CCN1 pre-mRNA in INA-6 cells. INA-6 cells
were incubated with varying concentrations of CCN1-Fc for 24 h.
Semi-quantitative PCR was performed with primers for CCN1 4-5 and
EEF1A1. Densitometric analysis was used to determine the amount
of intron-retaining and intron-free pre-mRNA isoform. Bar graphs
showing the percentage of intron-free isoform (intron-free mRNA
compared to total (intron-free + intron retained) mRNA), which is
enhanced by increased concentration of CCN1-Fc. EEF1A1 was used
to normalize data.
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pre-mature stop codon in intron 1 (Additional file 1:
Figure S1), translation of full-length CCN1 protein, as
well as truncated isoforms, could be excluded in INA-6
control cells since exon 1 only encodes for the signal
peptide, whereas intron-free CCN1 mRNA expressed by
INA-6 cells after MSC contact should be able to trans-
late the full-length protein. To analyze protein expres-
sion of CCN1, INA-6 control cells, as well as MSC co-
cultured INA-6 cells, were investigated by western blot
using the polyclonal antibody CYR61 H-78, raised
against amino acids located in the “hinge-region”. West-
ern blot analyses demonstrated that INA-6 cells co-
cultured with MSC showed a 345% increase in CCN1
protein levels in contrast to INA-6 control cells cultured
alone (Figure 1B). As only a small number of MSC res-
ide within the bone marrow, we additionally performed
co-culture experiments with INA-6 and osteoblasts, gen-
erated by incubating MSC with osteogenic differenti-
ation media for 14 days. CCN1 4-5 primers confirmed a
similar splicing pattern in INA-6 cells obtained after co-
culture with MSC (data not shown).
Exogenous stimulation by recombinant CCN1-Fc protein
induces CCN1 pre-mRNA splicing and transcription in
INA-6 cells in a concentration-dependent manner
Hirschfeld et al. previously described the splicing of in-
tron 3 in CCN1 pre-mRNA in association with breast
cancer progression as an oxygen- and pH-regulated
event [17,18]. In our case, neither incubation in hypoxic
(1% O2) nor acidic conditions led to splicing of CCN1 in
INA-6 cells (data not shown). Furthermore, indirect co-
culture experiments with trans-well inserts (data not
shown), as well as experiments with MSC-derived
conditioned media (MSC-CM) (Additional file 2:
Figure S2), was not sufficient to induce CCN1 mRNA
splicing in INA-6 cells. It has previously been shown that
exogenous stimulation using recombinant CCN1 protein
induced endogenous CCN1 production [40]. To deter-
mine if this effect was mediated through splicing, we in-
vestigated if splicing of CCN1 pre-mRNA occurs after
treatment with recombinant protein. Although CCN1 is
highly expressed by MSC [8], native protein concentra-
tion may rapidly diminish in solution due to aggregation
on MSC cell surface or cell culture dishes. Therefore, ex-
ogenous stimulation of INA-6 cells was performed by
using an Fc-tagged recombinant CCN1 protein (CCN1-
Fc), which is more stable in solution. INA-6 cells were
incubated with varying concentrations of recombinant
CCN1-Fc protein for 24 h and analyzed by PCR with
CCN1 intron-4 spanning primers (CCN1 4-5). Results
show that treatment with CCN1-Fc induced splicing of
CCN1 pre-mRNA in a concentration-dependent manner,
as represented by an increased amount of intron-freeRNA isoform compared to total CCN1 mRNA (Figure 2).
Incubation with 1 μg/ml CCN1-Fc increased the percent
of CCN1 mRNA in its intron-free form from 10%, ob-
served before recombinant protein addition, to 40% after
protein addition. This increased prevalence of intron-free
CCN1 mRNA was further enhanced to ~ 70% intron-free
mRNA by incubation with 2.5 μg/ml of recombinant pro-
tein. To evaluate if splicing is not only concentration
dependent, but also time dependent, we performed time
course experiments after 4 h, 8 h and 24 h. Concentra-
tions of CCN1-Fc which showed small to medium spli-
cing activity after 24 h incubation were used to allow
detection of enhanced splicing. Splicing plateaued within
4 h of incubation with recombinant protein concentra-
tions as low as 0.05 μg/ml (Additional file 3: Figure S3),
and remained consistent for up to 72 h after stimulation
with CCN1-Fc (data not shown). Splicing of CCN1 pre-
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event in response to CCN1 protein stimulation. To deter-
mine changes at the transcription level of CCN1 mRNA in
response to CCN1-Fc treatment, we measured overall inten-
sity of bands obtained with intron-4 spanning primers by
semi-quantitative PCR and densitometric analyses. Relative
to mRNA expression in Fc-Tag treated control cells, incuba-
tion with 1 μg/ml or 5 μg/ml CCN1-Fc led to a 1.8 fold in-
creased expression of CCN1 (Additional file 4: Figure S4A).
Similar results were obtained by qPCR with a second
intron-4 spanning primer pair. Treatment with 1 μg/ml
CCN1-Fc enhanced CCN1 mRNA expression by 1.4 fold,
2.5 μg/ml CCN1-Fc led to a 2.5 fold enhanced gene ex-
pression, which diminished to 2.1 fold after stimulation
with 5 μg/ml CCN1-Fc in comparison to Fc-Tag control
(Additional file 4: Figure S4B).Figure 3 Domain 4 of CCN1-Fc is required to induce CCN1 pre-mRNA
recombinant CCN1-Fc full-length protein, or an equivalent amount of trunc
Semi-quantitative PCR with intron-containing CCN1 primers showed that ex
did not induce complete CCN1 mRNA splicing. (B) Splicing of CCN1 pre-mR
GRGDSP peptide (50 μg/ml in culture media) but not by addition of the co
is shown.Domain 4 of CCN1-Fc is involved in inducing CCN1
pre-mRNA splicing
To characterize which domains of CCN1 are involved in
stimulating mRNA intron splicing, we incubated INA-6
cells with full length CCN1-Fc, as well as truncated iso-
forms comprising domain 1 (CCN1-Fc 1), domains 1 and 2
(CCN1-Fc 1-2) or domains 1-3 (CCN1-Fc 1-3). Only the
full length CCN1-Fc was able to induce the splicing of
CCN1mRNA for all introns while induction with truncated
CCN1-Fc showed only limited splicing of introns 1 and 2
(Figure 3A), highly suggestive that domain 4, also known as
the cysteine-knot containing module (CT), is necessary for
the induction of splicing of all introns. Because CCN pro-
tein functions are mediated mainly by integrin binding [41]
and because domain 4 contains several integrin binding
sites, we next blocked integrin-binding activity on INA-6splicing. (A) INA-6 cells were incubated with either 2.5 μg/ml
ated CCN1 isoforms (CCN1-Fc 1-3, CCN1-Fc 1-2, and CCN1-Fc 1).
posure to truncated CCN1 proteins comprising domains 1, 1-2, or 1-3
NA induced by 2.5 μg/ml full-length CCN1-Fc was reversed by
ntrol peptide GRADSP. One representative experiment out of three
Figure 4 CCN1-Fc enhances INA-6 cell viability in the absence
of IL-6. INA-6 cells were cultured with serum-reduced media for 24
h before stimulation with (A) CCN1-Fc or (B) CCN1-Fc and IL-6. After
24 h, cell viability was measured by quantification of ATP. In the
absence of IL-6, INA-6 cell viability was significantly enhanced when
stimulated with 0.1 μg/ml – 1 μg/ml CCN1-Fc, whereas incubation
with 0.05 μg/ml – 2.5 μg/ml CCN1-Fc led to a slight enhancement
of INA-6 cell viability in presence of IL-6. Results depicted graphically
represent the mean + SD for four independent experiments.
*p < 0.05 relative to control.
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the addition of full length CCN1-Fc. Incubation with
GRGDSP peptide inhibited splicing of intron 4 in contrast
to the control peptide GRADSP, which failed to inhibit spli-
cing of intron-free mRNA (Figure 3B). Comparing integrins
that are able to bind RGD motif in their ligands [42] with
integrin-binding sites located in the last domain of CCN1
[10], only αvβ3 integrin matched. To determine the type of
integrin responsible for the induction of CCN1 pre-mRNA
splicing, INA-6 cells were incubated with αvβ3 blocking
antibody and CCN1-Fc, which showed no reduction in spli-
cing (data not shown). We further performed blocking ex-
periments with anti-integrin β1, β2, β3, β7 antibodies, as
these integrins are described as being expressed on mye-
loma cells [43], and integrins α6β1 and αMβ2, which interact
with the CT-domain of CCN1 [10]. No anti-integrin anti-
body was able to block splicing mediated by stimulation
with CCN1-Fc (data not shown).
CCN1-Fc enhances INA-6 cell viability in the absence
of IL-6
It has previously been shown that survival of both INA-6
cells and primary myeloma cells is independent of IL-6
when cultured with MSC [38]. We next wanted to investi-
gate whether CCN1, as a MSC-derived factor, has a positive
effect on myeloma cell viability. Therefore, pre-starved
INA-6 cells were incubated with varying concentrations of
CCN1-Fc for 24 h, in the absence of IL-6, and cell viability
was assessed through quantification of ATP content. Cell
viability was increased by ~40% when treated with 0.05 μg/
ml or 2.5 μg/ml CCN1-Fc and further significantly en-
hanced to 50% when cells were incubated with 0.1 μg/ml or
1 μg/ml CCN1-Fc compared to control cells treated with
Fc-Tag (Figure 4A). Enhanced cell viability was not accom-
panied with reduced apoptosis induction or enhanced
phosphorylation of STAT3, Erk1/2 or p38 MAPK (data not
shown). Additionally, in the presence of IL-6, incubation
with 0.05 μg/ml - 2.5 µg/ml CCN1-Fc showed only a mar-
ginal 15% increase in cell viability while treatment with 5
μg/ml CCN1-Fc had no effect (Figure 4B).
Discussion
In the present study, we expand knowledge on regulatory
mechanisms involving splicing of the proangiogenic, matri-
cellular growth and differentiation factor CCN1/CYR61 in
the tumor microenvironment with a special focus on
myeloma-MSC interaction. Our new findings include
mechanistic data on the role of intron retention and spli-
cing as a means of translation regulation of immediate early
proteins of the CCN family as well as putative biological
functions of CCN1 as a factor promoting myeloma cell
viability.
CCN1, according to genetic mouse models and in vitro
signaling experiments, is involved in angiogenesis andanoikis [4,6,14,44,45]. It is expressed in regenerating/ prolif-
erating MSC and osteoblast precursors but not in mature
bone cells [7,8]. Earlier and recent reports have demon-
strated that CCN1 is expressed in MM myeloid and
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and prostate cancer, and may contribute to tumor cell sur-
vival by providing signals stimulating angiogenesis and sur-
vival through acquire anoikis resistance [14,44,46-48]. We
observed CCN1 intron splicing in INA-6 myeloma cells for
all four introns of the CCN1 mRNA and enhanced tran-
scription of CCN1 after co-culture with MSC. This extends
previous findings of intron splicing with regard only to in-
tron 3 in CCN1 mRNA of breast cancer cells [18]. The
presence of 2 pre-mature stop codons within this intron 3-
retaining mRNA sequence suggested the possible existence
of truncated CCN1 proteins containing domain 1 and 2.
However, our finding of intron 1-4 retention in myeloma
cells, and the presence of an in-frame stop codon down-
stream to the CCN1 signal sequence (within intron 1) im-
plies that intron 1-4 retaining CCN1 mRNA completely
blocks endogenous translation of full length CCN1 protein
in INA-6 cells, preventing translation of truncated variants
that could be termed isoforms resulting from alternative
splicing [15]. Moreover induction of splicing through con-
tact with MSC is initiated at all introns and allows for full
length protein expression in INA-6 cells, as confirmed by
the increase in CCN1 protein using an antibody directed
towards the hinge region. As this part of the protein offers
the most diversity to the other members of the CCN family
[11], antibodies directed against the variable linker region
will cause less cross-reactivity to other CCN proteins and
higher specificity than domain-specific antibodies.
In the case of breast cancer, alternative splicing of intron
3 in CCN1 pre-mRNA is regulated by hypoxia and acidosis
which further leads to disease progression [17,18]. In the
case of MM, changes in CCN1 mRNA splicing patterns ap-
pear independent of pH change and oxygen deficiency, nor
is it mediated by soluble factors, as indirect co-culture with
MSC using trans-well inserts, as well as by incubating with
MSC-derived conditioned media, was not sufficient to in-
duce CCN1 splicing in INA-6 cells. However, recombinant
human Fc-tagged CCN1 protein was capable of inducing
this phenomenon. We therefore hypothesized that the na-
tive CCN1 protein is rapidly aggregating on cell surfaces
and materials of cell culture flasks, and thus, is not available
(in sufficient quantity) in the soluble phase. This hypothesis
is further confirmed by previous findings that CCN1, al-
though it contains an N-terminal secretory signal peptide,
is not secreted into the supernatant and instead, remains
associated with the extracellular matrix, leading to restric-
tion of CCN1 action to the local microenvironment [49]. In
contrast the recombinant CCN1-Fc protein shows greater
stability in solution and induces CCN1 mRNA splicing
when added to cell cultures. As the amount of intron-free
isoform of CCN1 mRNA increased compared to total
CCN1 mRNA, and because increases in the intron-free iso-
form is accompanied with a decrease in the intron-retained
isoform, we suspect that splicing induction is an importantregulatory mechanism. In addition, densitometric analyses
and qPCR revealed that incubation with CCN1-Fc further
led to enhanced transcription of CCN1 mRNA, and that
this enhancement is a rapid process which responds in a
dose-dependent manner. As well as being a rapid process,
concentrations as low as 0.05 μg/ml CCN1-Fc was suffi-
cient to induce splicing, suggesting a highly sensitive re-
sponse to CCN1 levels. Additionally, once primed with
CCN1-Fc, splicing patterns were detectable up to three
days after stimulation, suggesting a long-lasting signature.
We conclude that CCN1 protein, delivered in a paracrine
manner, is an appropriate stimulus to initiate complete spli-
cing of intron-retaining CCN1 mRNA in myeloma cells,
which further leads to protein translation in the target cell,
maintaining further CCN1 expression in an autocrine man-
ner. The fact that CCN1 production in histological sections
of MM patients is located in cells that are not directly lo-
cated adjacent to bone-derived cells favors a long term sig-
nature in MM cells, which remains after contact with
CCN1-producing bone cells, though other stimulators can-
not be excluded. Production of CCN1 by myeloma cells in
addition to CCN1 derived from cells in the bone marrow
may further lead to an angiogenic switch that is associated
with disease progression [50].
CCN proteins are involved in many different cellular
functions depending on their interacting partners -
mainly integrins - expressed on the cell surface. The CT
domain, as well as the TSR and vWC domain, include
several integrin-binding sites that promote the activity of
CCN proteins [5,11,51]. The CT domain contains several
integrin-binding sites for α6β1, αMβ2, and αvβ3 integrins,
whereas the integrin α6β1 can bind the TSR domain and
integrin-binding sites for αvβ3, αvβ5, and αIIbβ3 are lo-
cated within the vWC domain [10,51]. Several integrins,
such as αvβ3 and αvβ5, bind their ligands by recognizing
RGD sequences [42]. To elucidate the mechanism in-
volved in splicing, we incubated INA-6 cells with full
length and truncated CCN1 proteins that contain do-
main 1-3, 1-2, or domain 1 only. Polypeptides lacking
domain 4 did not show any effect, suggesting that do-
main 4, also known as the CT domain, is necessary for
splicing induction. Furthermore, blocking RGD-dependent
integrins on INA-6 cells by pre-incubation with GRGDSP
peptide abolished CCN1-induced splicing in INA-6 cells,
supporting the hypothesis of an integrin-mediated mech-
anism. CCN1 does not contain an RGD sequence motif,
but RGD-blocking peptides have been previously re-
ported to also abolish other effects of CCN proteins [41].
Blocking antibodies targeting β-integrins (β1, β2, β3, and
β7) that are relevant in myeloma [43], as well as αvβ3, the
RGD-sensitive integrin comprised in CT domain, were
unable to prevent the splicing induction of CCN1 mRNA
by CCN1-Fc stimulation. We can only speculate on the
reason for this discrepancy, one of which may be that
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able antibodies. Thus, we suggest that splicing induction
may be a complex mechanism, dependent on engage-
ment of several integrins and/or co-receptors that require
further investigations.
In general, multiple myeloma cells, if removed from
the bone marrow, often cannot survive without feeder
cells or supplementation of factors to cell cultures, e.g.
IL-6 in case of the INA-6 cell line [52]. In the case of
co-culture with MSC, myeloma cells survive independ-
ent of the IL-6/gp130/STAT3 pathway [38] suggesting
that other pro-myeloma factors, such as CCN1, are pro-
vided by the stromal tumor microenvironment. We were
able to detect a significantly increased cell viability of
myeloma cells after CCN1 incubation independent of
IL-6 suggesting CCN1 as a microenvironment-derived
pro-myeloma factor. CCN1-dependent signaling path-
ways were not involved mechanistically in this pro-
myeloma effect as no alterations in phosphorylated p38,
ERK1/2, and STAT3 by CCN1 treatment of INA-6 cells
was observed.
Conclusions
Taken together, we show that INA-6 myeloma cells are able
to produce functional CCN1 protein after MSC contact,
which is induced by a splicing event concerning all introns
as well as enhanced transcription. MSC-dependent splicing
that governs CCN1 protein translation, as shown here, is
extremely relevant in both physiologic processes like regen-
eration and in tumor development, e.g. by enhancing angio-
genesis, especially in myeloma bone disease. MSC have
been reported to support or to suppress tumorigenesis and
this is certainly one of the more protective effects [53].
MSC-based treatment strategies in MM must be critically
examined with regard to the oncogenic splicing switch po-
tential of CCN1. In order to survive within the bone mar-
row, MM cells produce a series of modulatory factors for
osteogenic differentiation to suppress e.g. osteoblast-
derived inhibitory factors for MM growth and survival
[26,32,54,55]. In addition, MM cells, by either physical con-
tact or humoral factors, stimulate stromal osteogenic pre-
cursors to produce supportive factors, e.g. IL-6. Such
contact-mediated signatures of the transcriptome in stro-
mal osteogenic precursors may also persist as a permissive
situation in myeloma cells. Our findings suggest CCN1 as a
MSC-induced factor with relevance in tumor relapse and
development of secondary malignancies.
Methods
Ethics statement
Bone material was used according to the permission of
the local Ethics Committee (Medical Faculty of the Uni-
versity of Wuerzburg) and after having obtained written,
informed consent of each patient.Reagents and antibodies
Primary antibodies for western blot analyses were
directed against: CCN1 (CYR61 H-78, rabbit, sc-13100;
Santa Cruz Biotechnology, Heidelberg, Germany),
Tyr705-phosphorylated STAT3 (rabbit mAb, #9145;
New England Biolabs (NEB), Beverly, MA, USA),
Thr202/Tyr204 phosphorylated p44/42 MAPK (ERK1/
2) (rabbit, #9101; NEB), and Thr180/Tyr182 p38 MAPK
(rabbit mAb, #9215; NEB). Loading control antibodies
were specific for: β-actin (rabbit mAb, #4970; NEB),
STAT3 (rabbit, #4904; NEB), p42/44 MAPK (mouse
mAb, #4696; NEB), and p38α MAPK (mouse mAb,
#9217; NEB). Anti-rabbit antibody (goat-anti-rabbit IgG
(whole molecule)-peroxidase, A0545; Sigma Aldrich
Chemie (Sigma), Schnelldorf, Germany) and anti-mouse
antibody (goat-anti-mouse IgG (Fab specific)-peroxid-
ase, A9917; Sigma) were used as secondary antibodies.
To block RGD-dependent integrins, blocking peptide
(Gly-Arg-Gly-Asp-Ser-Pro, GRGDSP, SCP0157) and
control peptide (Gly-Arg-Ala-Asp-Ser-Pro, GRADSP,
SCP0156) were purchased from Sigma. The following
functional-blocking antibodies against several integrins
were obtained: β1 (monoclonal mouse IgG1, MAB
17781; R & D Systems (R & D), Wiesbaden, Germany),
β2 (antigen affinity purified polyclonal goat IgG, AF
1730; R & D), β3 (monoclonal mouse IgG1, NBP1-
28398; Novus Biologicals, Littleton, CO, USA), β7
(monoclonal rat IgG2a, κ, 321218; BioLegend, San
Diego, CA, USA), αvβ3 (monoclonal mouse IgG1, MAB
3050; R & D). Isotype antibodies were used as control:
Rat IgG2a, κ (400516; BioLegend), mouse IgG1
(MAB002; R & D), normal goat IgG (sc-2028; Santa
Cruz).
Cell culture
Primary MSC of healthy donors were isolated from bone
marrow of femoral heads after total hip arthroplasty and
characterized as previously described [8,56]. MSC were
selected by surface adherence and expanded in DMEM/
Ham’s F-12 (1:1) (PAA Laboratories (PAA), Linz,
Austria) supplemented with 10% (vol/vol) FCS (Bio-
chrom, Berlin, Germany), 1 U/ml penicillin, 100 μg/ml
streptomycin (PAA) and 50 μg/ml L-ascorbic acid 2-
phosphate (Sigma). All experiments were performed
with MSC in passage 1. Osteogenic precursor cells
(OPC) were generated by incubating MSC with osteo-
genic differentiation media for 14 days. Osteogenic dif-
ferentiation media consisting of DMEM High Glucose
media (PAA) with 10% (vol/vol) FCS, 1 U/ml penicillin,
100 μg/ml streptomycin and additionally supplemented
with 10 mM β-glycerophosphate disodium salt hydrate
(Sigma), 100 nM dexamethasone (Sigma) and 50 μg/ml
L-Ascorbic acid-2-phosphate sesquimagnesium salt hy-
drate (Sigma). Osteogenic differentiation was checked
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the Alkaline Phosphatase, Leukocyte Kit 86-C (Sigma)
and mineralized extracellular matrix was visualized by
staining with alizarin red S (Sigma). The cell line INA-6
[52] was maintained in RPMI 1640 complete medium
that is generated by adding 20% (vol/vol) FCS, 100 μg/
ml gentamycine, 2 mmol/l glutamine (PAA), 1 mmol/l
Na-pyruvate (Sigma) to RPMI 1640 media (PAA, Linz,
Austria). INA-6 cells were cultivated with a final concen-
tration of 2 ng/ml recombinant human interleukin-6
(IL-6; R & D). For measuring cell viability and apoptosis,
INA-6 cells were pre-starved by incubating with serum
reduced RPMI 1640 complete medium containing 4%
(vol/vol) FCS and 2 ng/ml IL-6 for 24 h. Starvation
media permits cultivation of INA-6 cells over 48 h with-
out inducing enhanced cell death compared to control
(proved by trypan blue exclusion). All cell cultures were
regularly tested for mycoplasma and grown at 37°C and
5% CO2. For experiments under hypoxic conditions, cul-
tures were incubated in an incubator adjusted to 1% O2.
In parallel, control cells were cultured under normoxia
(21% O2). Acidic conditions were generated by culturing
INA-6 cells in consumed media.Direct and indirect co-cultures of MM cells with MSC
5×105 MSC were seeded per well (6-well plate) and given
time to attach for one day. 2×106 INA-6 cells, washed once
with PBS, were either added to the MSC or cultured with 2
ng/ml IL-6 (control) in a mixture of DMEM/Ham’s F12
and RPMI 1640 (1:1). After 24 h of co-culture, INA-6 cells
were carefully rinsed off the MSC layer with PBS. To pre-
vent contamination of INA-6 cells with MSC, rinsing was
performed with regard to leaving the MSC layer intact as
well as by staining INA-6 cells with CellTracker™ Green 5-
chloromethylfluorescein diacetate (CMFDA, 5 μM; PA-
3011, Lonza Group, Basel, Switzerland) according to the
manufacturer’s instructions before performing co-culture.
Detached INA-6 cells were examined afterwards by using a
fluorescence microscope (Microscope Axiovert 25; Zeiss,
Jena, Germany). As no unstained cells were detected, con-
tamination with MSC was excluded. In the case of indirect
co-culture using trans-well inserts, MSC were seeded as
previously described on 6-well tissue culture polystyrene
plates (Corning, NY, USA) and INA-6 cells were transferred
on polyester membrane insert (0.4 μm pore size).Preparation of MSC-derived conditioned media (MSC-CM)
MSC-CM was generated from MSC supernatant after
48-72 h of culture after passing through a 0.2 μm filter
to eliminate remained cellular debris and contaminating
cells. In parallel, 2×106 INA-6 cells were centrifuged at
1200 rpm and cell pellet was resuspended in 5 ml MSC-
CM or, in the case of control, in 5 ml MSC media,supplemented with 2 ng/ml IL-6 and incubated for 24 h.
The next day, cells were harvested for RNA isolation.
Protein extraction and western blot analyses
For CCN1 detection, INA-6 control cells were cultured
with 2 ng/ml IL-6 or co-cultured with MSC and har-
vested as described above. To investigate signaling path-
ways, INA-6 cells were incubated with IL-6-deprived
media for 20 h, washed, and stimulated with CCN1-Fc
or Fc-Tag for 30 min or 60 min after starving for 4 h in
serum-free media.
To generate whole cell lysates, cells were washed with
PBS and incubated with lysis buffer (#9803; NEB) supple-
mented with complete, EDTA-free protease inhibitor cock-
tail (#04693132001; Roche, Mannheim, Germany) and
PhosStop phosphatase inhibitor cocktail (#0496845001;
Roche) for 10 min on ice. After sonication with an ultra-
sonic homogenizer (Sonopuls, Bandelin), cell lysates were
cleared by centrifugation (12000 rpm, 15 min, 4°C). Protein
concentrations were determined using the Bradford assay
(Roti®-Quant; Carl Roth, Karlsruhe, Germany). Equal
amounts of proteins mixed with Laemmli buffer were
heated up to 95°C for 5 min and run on sodium dodecyl
sulphate 10%-polyacrylamide gels before blotting on polyvi-
nyldifluoride (PVDF) membranes (WESTRAN® clear signal;
GE Healthcare Europe GmbH, Freiburg, Germany). Blots
were incubated in blocking buffer (p38α MAPKp44/42
MAPK (Erk1/2), After four washes with buffer, the blots
were incubated with corresponding peroxidase-conjugated
secondary antibody in corresponding blocking buffer for 2
h at room temperature. Visualization of the blots was per-
formed with the enhanced chemiluminescence (ECL) sys-
tem (Amersham ECL Prime Western Blotting Detection
Kit; GE Healthcare Europe GmbH, Freiburg, Germany) and
X-ray films (Fuji Medical X-ray film Super RX, Fujifilm
Europe GmbH, Düsseldorf, Germany). Loading was deter-
mined by stripping the membrane and re-blotting with cor-
responding control antibody.
RNA isolation and polymerase chain reaction (PCR)
Total RNA was isolated from INA-6 cells using the
NucleoSpin® RNA II kit (Machery-Nagel GmbH & Co.
KG, Düren, Germany) according to the manufacturer’s
instructions. Purity and yield of the RNA were photo-
metrically determined. cDNA was synthesized by using 1
μg of total RNA, random primers (Life Technologies
GmbH, Darmstadt, Germany), and M-MLV reverse tran-
scriptase (Promega GmbH (Promega), Mannheim,
Germany) according to the manufacturer’s instructions.
Semi-quantitative PCR analyses were carried out in a vol-
ume of 30 μl containing 6 μl 5× Green GoTaq® Flexi Buffer
(#M891A, Promega), 20 ng cDNA, 1.7 mM MgCl2
(#A351H; Promega), 0.3 mM dNTPs (Bioline, Luckenwalde,
Germany), 1 unit GoTaq® DNA Polymerase (Promega) and
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Ebersberg, Germany) for CCN1 gene or the housekeeping
gene eukaryotic translation elongation factor 1 alpha 1
(EEF1A1). Intron-spanning primer sequences for CCN1 (ac-
cession number DNA sequence: NC_000001.10) were ob-
tained by using the online software Primer3Plus (see Table 1
for primer sequences). PCR was run in a peqSTAR 2×
thermocycler (Peqlab Biotechnologie GmbH, Erlangen,
Germany) as follows: 2 min at 95°C, 95°C for 30 sec, 50-56°
C for 30 sec (EEF1A1 and intron-4 spanning CCN1 primer
(CCN1 4-5)) or 45 sec, and 72°C for 1 min (37-43 cycles
for CCN1, 22-25 cycles for EEF1A1), finished by 72°C for 3
min. For long-range PCR primer pairs CCN1 1-2 forward
and CCN1 4-5 reverse were used. Annealing temperature
was adjusted to 52°C, elongation time to 2 min. Separation
of 10 μl of PCR products occurred on a 2% agarose gel
containing GelRed® (#M3199; Genaxxon Bioscience GmbH,
Ulm, Germany). Specificity of PCR products was verified
by sequence analyses using Big Dye Terminator v1.1 Cycle
Sequencing Kit and ABI 3130xL Genetic Analyzer (Applied
Biosystems, Darmstadt, Germany).
Quantitative real-time PCR (qPCR) was performed in
a volume of 20 μl with 1 μl of cDNA, which was previ-
ously diluted 1:5, 10 μl KAPA SYBR FAST Universal
qPCR Master Mix (Peqlab Biotechnologie GmbH,
Erlangen, Germany) and 1 pmol each forward and reverse
primers (biomers.net GmbH, Ulm, Germany) by using
Opticon DNA Engine (MJ Research, Watham, USA).
Amplification of CCN1 gene was performed by using
primers specific for exons 4-5 (5′-primer, 5′-ACGAGT
TACCAATGACAACC-3′; 3′-primer, 5′-CCAGCGTAA
GTAAACCTGAC-3′). As an internal control, mRNA ex-
pression level of housekeeping gene RPS27A was ampli-
fied with following sequence specific primers (5′-primer;
5′-TCGTGGTGGTGCTAAGAAAA-3′; 3′-primer, 5′-
TCTCGACGAAGGCGACTAAT-3′). QPCR conditions
were as follows: 95°C, 3 min; 40 cycles: 95°C, 15 s; 60°C
for RPS27A, 57°C for CCN1, 15 s; 72°C, 20 s; followed
by melting curve analysis for specificity of qPCR prod-
ucts. qPCRs were performed three times, results were
calculated with the ΔΔct method and significances
with the Relative Expression Software Tool (REST
2009 V2.0.13) obtained from Qiagen GmbH (Hilden,
Germany) [39].
Expression and purification of recombinant CCN1 protein
(CCN1-Fc) and CCN1 domains (CCN1-Fc 1-3, CCN1-Fc 1-2,
CCN1-Fc 1)
The cloning of CCN1, as well as the preparation of the
virus stock of CCN1-Fc, was generated as previously de-
scribed [57]. Additionally, to express recombinant
CCN1-Fc proteins lacking domain 4 (CCN1-Fc 1-3), do-
mains 3 and 4 (CCN1-Fc 1-2) or domains 2-4 (CCN1-Fc
1), respectively, corresponding open reading frames weresimilarly cloned and expressed. To purify the CCN1-Fc
protein, as well as the domain-lacking proteins or Fc-Tag
protein, 1 ml HiTrap Protein G HP columns were used
with a peristaltic pump P-1 (GE Healthcare Europe
GmbH, Freiburg, Germany). 75 ml cell supernatant was
filtered (0.2 μm) and transferred to a PBS equilibrated
column. Columns were washed with PBS for 15 min be-
fore protein was eluted with elution buffer (0.1 M gly-
cine, pH 2.2). Previously provided 3M Tris/HCl, pH 8
immediately neutralized eluted protein fractions. Protein
was further used for gel electrophoresis and purity was
checked by silver staining and western blotting using Fc-
Tag antibody, as previously described [57]. Proteins were
stored at -20°C until use. After thawing, the tube was
centrifuged and after transferring the supernatant into a
fresh tube, protein concentration was determined by
Bradford assay.
Treatment of INA-6 cells with CYR61-Fc and truncated
CYR61-Fc proteins
INA-6 cells were seeded in 24 well-plates (3×105 cells/well)
and treated with CCN1-Fc, truncated CCN1-Fc isoforms,
or Fc-Tag for control. The quantity of truncated proteins or
Fc-Tag was added in equimolar concentration compared to
the full-length protein CCN1-Fc. At indicated time points,
cells were harvested for RNA isolation.
For blocking integrin signaling, INA-6 cells were
seeded as mentioned above and pre-incubated for 45
min with 55 μg/ml GRGDSP peptide (control: GRADSP
peptide) or 22 μg/ml anti-integrin antibody (control: iso-
type antibody) at 37°C and 5% CO2. For 24 h incubation,
CCN1-Fc or Fc-Tag was added as previously described at
a final concentration of 50 μg/ml peptide or 20 μg/ml
anti-integrin antibody.
Cell viability assays
Pre-starved INA-6 cells were washed once with PBS, re-
suspended in starvation media with or without IL-6 and
seeded in a 96-well plate (1250 cells/well). To assess the
influence of CCN1-Fc on cell viability, INA-6 cells were
stimulated in triplicate for 24 h with CCN1-Fc at a final
concentration ranging from 0.1 μg/ml to 5 μg/ml, or
with Fc-Tag (1.9 μg/ml; adapted to the highest CCN1-Fc
concentration) for control. Proliferation was quantified
by CellTiter-Glo® Luminescent Cell Viability Assay and
apoptosis was determined by CaspaseGlo® 3/7 Assay
(both Promega) according to the manufacturer’s instruc-
tions and by measuring luminescence with an Orion II
luminometer (Berthold Detection Systems, Pforzheim,
Germany).
Statistical analysis
Results were expressed as mean + SD from four inde-
pendent experiments. Influence of CCN1-Fc on cell
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analysis with Dunn’s post-hoc multiple comparison test
using GraphPad Prism 6.03 (GraphPad Software, CA,
USA). P values less than 0.05 were considered to be sta-
tistically significant. Significances of qPCR analysis was
calculated with the Relative Expression Software Tool
(REST 2009 V2.0.13) obtained from Qiagen GmbH
(Hilden, Germany) [39].Additional files
Additional file 1: Figure S1. Nucleotide sequence of CCN1 gene. CCN1
sequence (accession number DNA sequence: NC_000001.10) including
coding sequence (CDS) (underlined), parts of exon 1 and 2 (capital
letters), intron 1 (gray, lower case letters) and stop codon (box). Arrows
represent location of CCN1 1-2 primers.
Additional file 2: Figure S2. Splicing of CCN1 is not induced in INA-6
cells by MSC-derived conditioned media (MSC-CM). INA-6 cells were
cultured either alone (-) or with CM of three different MSC donors (+).
After 24 h of incubation, INA-6 cells were harvested and splicing pattern
of CCN1 pre-mRNA was investigated by semi-quantitative PCR and
intron-4 spanning primers. Both, control cells (-) and cells incubated with
CM (+) expressed the intron-retaining RNA isoform. Housekeeping gene
EEF1A1 served as control.
Additional file 3: Figure S3. Splicing of CCN1 is a rapid, concentration-
dependent event in INA-6 cells. INA-6 cells were incubated with varying
concentrations of CCN1-Fc for 4 h, 8 h, or 24 h. (A) Afterwards, splicing of
CCN1 was determined by semi-quantitative PCR and by using primers for
exons 4-5 (CCN1 4-5), whereas EEF1A1 served as control. (B) Bar graphs display
the relative expression of intron-free isoform, which increases with
concentration but not with duration of incubation.
Additional file 4: Figure S4. Incubation with CCN1-Fc promotes CCN1
transcription in INA-6 cells. (A-B) INA-6 cells were incubated with Fc-Tag
(control) or varying concentrations of CCN1-Fc for 24 h. After total RNA
isolation, (A) semi-quantitative PCR, using primers for exons 4-5 (CCN1
4-5), and (B) qPCR analyses, using intron 4 spanning primers, were
performed for CCN1 mRNA expression. Data were normalized relative to
mRNA expression levels of housekeeping gene (A) EEF1A1 or (B) RPS27A.
Results were normalized to Fc-Tag-incubated control cells, which were
defined as 1. Results shown in (B) represent mean + SD of triplicate
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